Colleen A. Lawton, MD, FACR, FASTRO

Publications

• In Reply to Onal et al.

  (Hall WA, Lawton CAF, coauthors.) Int J Radiat Oncol Biol Phys. 2021 Jun 01;110(2):620-621 PMID: 33989589 SCOPUS ID: 2-s2.0-85105339930 05/15/2021

• Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial.

  (Hall WA, Bedi M, Kilari D, Bylow KA, Burfeind J, Johnstone C, Siker M, Currey A, See WA, Nelson A, Johnson S, Straza M, Lawton CAF.) Pract Radiat Oncol. 2021 Apr 10 PMID: 33848618 SCOPUS ID: 2-s2.0-85107984420 04/14/2021

• Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.

  (Spratt DE, Malone S, Roy S, Grimes S, Eapen L, Morgan SC, Malone J, Craig J, Dess RT, Jackson WC, Hartman HE, Kishan AU, Mehra R, Kaffenberger S, Morgan TM, Reichert ZR, Alumkal JJ, Michalski J, Lee WR, Pisansky TM, Feng FY, Shipley W, Sandler HM, Schipper MJ, Roach M 3rd, Sun Y, Lawton CAF.) J Clin Oncol. 2021 01 10;39(2):136-144 PMID: 33275486 PMCID: PMC8189640 12/05/2020

• Considering benefit and risk before routinely recommending SpaceOAR.

  (Hall WA, Tree AC, Dearnaley D, Parker CC, Prasad V, Roach M 3rd, Lawton CAF.) Lancet Oncol. 2021 01;22(1):11-13 PMID: 33387489 SCOPUS ID: 2-s2.0-85098657879 01/03/2021

• NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer.

  (Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, Tree AC, Efstathiou JA, Harisinghani M, Jani AB, Buyyounouski MK, Pisansky TM, Tran PT, Karnes RJ, Chen RC, Cury FL, Michalski JM, Rosenthal SA, Koontz BF, Wong AC, Nguyen PL, Hope TA, Feng F, Sandler HM, Lawton CAF.) Int J Radiat Oncol Biol Phys. 2021 01 01;109(1):174-185 PMID: 32861817 PMCID: PMC7736505 SCOPUS ID: 2-s2.0-85092542250 08/31/2020

• A Prospective Multi-Institutional Phase I/II Trial of Step-Wise Dose-per-Fraction Escalation in Low and Intermediate Risk Prostate Cancer.

  (Ritter MA, Kupelian PA, Petereit DG, Lawton CA, Anger N, Geye H, Chappell RJ, Forman JD.) Pract Radiat Oncol. 2020 Sep - Oct;10(5):345-353 PMID: 32169590 PMCID: PMC7483248 03/15/2020

• First, Do No Fistulization.

  (Lawton CAF.) Int J Radiat Oncol Biol Phys. 2020 08 01;107(5):866 PMID: 32698976 07/24/2020

• To Radiate or Not to Radiate-The Challenges of Pelvic Reirradiation.

  (Kamran SC, Zelefsky M, Nguyen PL, Lawton CAF.) Semin Radiat Oncol. 2020 Jul;30(3):238-241 PMID: 32503789 06/07/2020

• Digital Rectal Examination Remains a Key Prognostic Tool for Prostate Cancer: A National Cancer Database Review.

  (Borkenhagen JF, Eastwood D, Kilari D, See WA, Van Wickle JD, Lawton CA, Hall WA.) J Natl Compr Canc Netw. 2019 07 01;17(7):829-837 PMID: 31319388 SCOPUS ID: 2-s2.0-85070084884 07/19/2019

• Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.

  (Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR Jr, Shipley WU, Sandler HM.) Lancet Oncol. 2018 11;19(11):1504-1515 PMID: 30316827 PMCID: PMC6540797 SCOPUS ID: 2-s2.0-85057161270 10/15/2018

• Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer.

  (Lukka HR, Pugh SL, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M 3rd, Pinover WH, Beyer DC, Amanie JO, Sandler HM, Kachnic LA.) Int J Radiat Oncol Biol Phys. 2018 10 01;102(2):287-295 PMID: 29913254 PMCID: PMC6248906 06/19/2018

• Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities.

  (Xiao C, Moughan J, Movsas B, Konski AA, Hanks GE, Cox JD, Roach M 3rd, Zeitzer KL, Lawton CA, Peters CA, Rosenthal SA, Hsu IJ, Horwitz EM, Mishra MV, Michalski JM, Parliament MB, D'Souza DP, Pugh SL, Bruner DW.) Adv Radiat Oncol. 2018 Jul-Sep;3(3):405-411 PMID: 30202809 PMCID: PMC6128023 09/12/2018